Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 11 - 20 of about 100   

Articles published

CBST 74.96 +0.11 (0.15%)
price chart
Cubist Pharmaceuticals Antibiotic Accepted for EU Review
The European Medicines Agency (EMA) accepted Cubist Pharmaceuticals, Inc.'s (CBST - Analyst Report) Marketing Authorization Application (MAA) for its investigational antibiotic, ceftolozane/tazobactam.
Cubist Pharmaceuticals' Antibiotic Accepted for EU Review - Analyst Blog  NASDAQ
Cubist to Present New Data from Antibiotics Portfolio at 54th Interscience ...  Business Wire (press release)
Related articles »  
Cubist Pharmaceuticals (CBST) Marked As A Barbarian At The Gate
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Trade-Ideas LLC identified Cubist Pharmaceuticals ...
Related articles »  
Cubist Recalls Its Lifesaving Drug Cubicin
Cubist Pharmaceuticals Inc (CBST) announced yesterday, it is recalling 101 production lots of its antibiotic Cubicin (daptomycin injection) amid fear of glass particles being present in the drug.
Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Nine Lots of ...  MarketWatch
Cubist Pharma Recalls Some Vials of Antibiotic Cubicin  Medscape
Related articles »  
Cubist Pharmaceuticals Upgraded to Neutral by Zacks (CBST)
Cubist Pharmaceuticals Inc logo Zacks upgraded shares of Cubist Pharmaceuticals (NASDAQ:CBST) from an underperform rating to a neutral rating in a research report released on Friday morning.
Investor Watch List: Cubist Pharmaceuticals Inc. (CBST), Baker Hughes ...  WallStreet Scope
Related articles »  
Cubist Pharmaceuticals Rating Lowered to Neutral at Credit Suisse (CBST)
Cubist Pharmaceuticals Inc logo Cubist Pharmaceuticals (NASDAQ:CBST) was downgraded by equities researchers at Credit Suisse from an �outperform� rating to a �neutral� rating in a research report issued on Thursday, TheFlyOnTheWall.
Cubist Pharmaceuticals (CBST), Durata Therapeutics, Inc. (DRTX) PT Raised at ...
BofA/Merrill Lynch analyst Steve Byrne raised his price target on Buy-rated Cubist Pharmaceuticals (NASDAQ: CBST) to $89.00 (from $84.00) after the company announced approval for Sivextro in skin infections caused by MRSA. In the same report, the ...
Jefferies Raises Price Target On Cubist Pharmaceuticals
The analyst is expecting shares to appreciate as the company starts to release its drug. In addition, as two more antibiotics are launching this year, the firm is expecting Cubist to improve its operating/profit margins in 2015. Current quarter ...
Related articles »  
Pre Market Movers: Cubist Pharmaceuticals Inc (NASDAQ:CBST), Childrens ...
Cubist Pharmaceuticals Inc (NASDAQ:CBST) has been in the news recently after posting a stellar set of earning results. The company was upgraded to a buy at Credit Suisse for the near term which is seen as a huge positive.
Credit Suisse Downgrades Cubist Pharmaceuticals to Neutral (CBST)  Watch List News (press release)
Related articles »  
Cubist Pharma Posts Weak Earnings on Soft Cubicin Sales
Cubist Pharmaceuticals Inc.'s (CBST - Analyst Report) first quarter 2014 earnings (excluding special items) of 10 cents per share fell well short of the Zacks Consensus Estimate of 34 cents due to lower-than-expected revenues.
Cubist Pharmaceuticals Q3 14 Earnings Conference Call At 5:00 PM ET
Comment. More Sharing ServicesShare | Share on facebook Share on twitter Share on email Share on print Subscribe. ( - Cubist Pharmaceuticals Inc (. CBST. Cubist Pharmaceuticals Inc. CBST 73.37 +0.63 (0.86%). Powered by Market IQ. ) ...